GoodRx Holdings, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated June 14, 2023, details the results of GoodRx Holdings, Inc.'s Annual Meeting of Stockholders. The meeting was held to vote on director elections, auditor ratification, and executive compensation.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting outcomes.
Material Changes and Voting Results
Approximately 99.4% of the combined voting power of Class A and Class B common stock was present or represented by proxy. The following proposals were approved:
- Director Elections (Item 1): Stockholders elected four Class III directors: Julie Bradley, Dipanjan Deb, Stephen LeSieur, and Gregory Mondre. All candidates received overwhelming support with over 3.16 billion votes "FOR" each.
- Auditor Ratification (Item 2): Stockholders ratified the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2023.
- Executive Compensation (Item 3): Stockholders approved, on an advisory non-binding basis, the compensation of the Company's named executive officers.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, contingencies, or unusual items. The document is limited to the reporting of the stockholder vote results.
Key Facts for Investor Verification
- Verify the terms of office for the newly elected Class III directors, which expire at the 2026 Annual Meeting.
- Confirm the engagement of PricewaterhouseCoopers LLP for the 2023 fiscal year audit.
- Note the high level of stockholder participation (99.4%) and the strong approval margins for all proposals.